A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer

Cancer Investigation

Volumn 30, Issue 4, 2012, Pages 309-316

  Dittrich, Christian ^a   Solska, Ewa ^b   Manikhas, Alexey ^c   Eniu, Alexandru ^d   Tjulandin, Sergei ^e   Anghel, Rodica ^f   Musib, Luna ^g   Frimodt Moller, Bente ^g   Liu, Yushan ^h   Krejcy, Kurt ^g   Láng, István ⁱ  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

^b Wojewodzkie Centrum Onkologii W   (Poland)

^c Oncological Dispensary   (Russian Federation)

^d Institutul Oncologic i Chiricuta   (Romania)

^e N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^f Institutul Oncologic Bucharest ^*  (Romania)

^g ELI LILLY AND COMPANY   (United States)

^h I3 Statprobe   (United States)

ⁱ NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Breast cancer; Failed standard adjuvant therapy; Multitargeted antifolate; Pharmacokinetics; Randomized phase II trial

Indexed keywords

CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FOLIC ACID; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; AGRANULOCYTOSIS; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84860176719     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.658938     Document Type: Article

References (42)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-592. (Pubitemid 46359643)
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomized trials. Lancet 2005;365:1687-1717.
3. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Türlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-1144. (Pubitemid 47244357)
4. De Laurentiis M, Cancello G, DAgostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008;26:44-53.
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
6. Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 1997;17:146S-154S. (Pubitemid 27411255)
7. Joslin CA, Kunkler PB, Evans IH, Jones V, Wong K. Cyclophosphamide in the management of advanced breast cancer. Proc Roy Soc Med 1970;63:81-84.
8. Bramwell VH, Howell A, Anderson H, Rankin EM. Intermediate dose single-agent cyclophosphamide chemotherapy of advanced breast cancer. Clin Oncol 1983;9:251-256. (Pubitemid 13006202)
9. Carter SK, Livingston RB. Cyclophosphamide in solid tumors. Cancer Treat Rev 1975;2:295-322.
10. Schilsky RL. Biochemical pharmacology of chemotherapeutic drugs used as radiation enhancers. Semin Oncol 1992;19(Suppl. 11):2-7.
11. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-1123. (Pubitemid 27138611)
12. Adjei AA. Pemetrexed (Alimta®): a novel multi-targeted antifolate agent. Expert Rev Anticancer Ter 2003;3:145-156. (Pubitemid 36503392)
13. Dittrich C. Use of pemetrexed in breast cancer. Semin Oncol 2006;33(Suppl. 9):S24-S28.
14. Gomez HL, Santillana SL, Vallejos CS, Velarde R, Sanchez J, Wang X, Bauer NL, Hockett RD, Chen VJ, Niyikiza C, Hanauske AR. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006;12:832-838. (Pubitemid 43259865)
15. Miles DW, Smith IE, Coleman RE, Calvert AH, Lind MJ. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 2001;37:1366-1371. (Pubitemid 32588747)
16. Martin M, Spielmann M, Namer M, duBois A, Unger C, Dodwell D, Vodvarka P, Lind M, Calvert H, Casado A, Zelek L, Lluch A, Carrasco E, Kayitalire L, Zielinski C. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol 2003;14:1246-1252. (Pubitemid 37039051)
17. O'Shaughnessy JA, Clark RS, Blum JL, Mennel RG, Snyder D, Ye Z, Liepa AM, Melemed AS, Yardley DA. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 2005;6:143-149. (Pubitemid 40975610)
18. Llombart-Cussac A, Teodoulou M, Rowland K, Clark RS, Naka-mura T, Carrasco E, Cruciani G. Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study. Clin Breast Cancer 2006;7:380-385. (Pubitemid 46157558)
19. Dittrich C, Petruzelka L, Vodvarka P, Gneist M, Janku F, Kysela T, Melemed A, Latz J, Simms L, Krejcy K. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. Clin Cancer Res 2006;12:7071-7078. (Pubitemid 44974506)
20. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint defnitions and toxicity criteria. Invest New Drugs 1992;10:239-253. (Pubitemid 23008970)
21. Cockcrof DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
22. Hanauske AR, Dittrich C, Otero J. Overview of phase I/II pemetrexed studies. Oncology 2004;18(Suppl. 8):18-25.
23. Spielmann M, Martin M, Namer M, duBois A, Unger C, Dodwell DJ. Activity of pemetrexed (ALIMTA®, multi-targeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clin Breast Cancer 2001;2:47-51. (Pubitemid 32440423)
24. Latz JE, Chaudhary A, GhoshA,Johnson RD. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 2006;57:401-411. (Pubitemid 43087583)
25. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 2005;44:1135-1164. (Pubitemid 41483700)
26. de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJTFD, Wesseling J, van de Vijver M, Wessels LFA, Rodenhuis S. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 2010;119:119-126.
27. Barrios CH, Sampaio C, Vinholes J, Caponero R. What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Ann Oncol 2009;20:1157-1162.
28. Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart-Cussac A, Bozhok A, Martinez-Agullo A, Greco M, Byakhov M, Lopez JJ, Mansutti M, Valagussa P, Bonadonna G. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fuorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009;27:2474-2481.
29. Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS, Gelber RD, Green MD, Peccatori F, Cinieri S, Aebi S, Viale G, Price KN, Goldhirsch A; for the International Breast Cancer Study Group. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 afer prolonged follow-up. Ann Oncol 2009;20:1344-1351.
30. Stockler MR, Harvey VJ, Francis PA, Bryne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS. Capecitabine versus classical cyclophosphamide, methotrexate, and fuorouracil as frst-line chemotherapy for advanced breast cancer. J Clin Oncol 2011;29:4498-4504.
31. von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R, Marschner N, Kleeberg U, Tsekov C, Fritze D, Tomssen C, Stuart N, Vermorken JB, Loibl S, Merkle KH, Kaufmann M. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multi-centre trial of bendamustine hydrochlo-ride, methotrexate and 5-fuorouracil (BMF) versus cyclophos-phamide, methotrexate and 5-fuorouracil (CMF) as frst-line treatment of MBC. Anticancer Drugs 2005;16:871-877. (Pubitemid 41215753)
32. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as frst-line treatment for metastatic breast cancer. J Clin Oncol 2008;26:5544-5552.
33. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for frst-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-1260.
34. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New Engl J Med 2007;357:2666-2676.
35. Perez EA. Carboplatin in combination therapy for metastatic breast cancer. Oncologist 2004;9:518-527.
36. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O'Shaughnessy J. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26:3950-3957.
37. Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Lück HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Terasse P. Taxanes alone or in combination with anthracy-clines as frst-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008;26:1980-1986.
38. Garin A, Manikhas A, Biakhov M, Chezhin M, Ivanchenko T, Krejcy K, Karaseva V, Tjulandin S. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2008;110:309-315. (Pubitemid 351793878)
39. Ma CX, Steen P, Rowland KM, Niedringhaus RD, Fitch TR, Kugler JW, Hillman DW, Perez EA, Ingle JN, Adjei AA. A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: a NCCTG study. Ann Oncol 2006;17:226-231. (Pubitemid 43160110)
40. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors. Eur J Cancer 2006;42:2433-2453. (Pubitemid 44442936)
41. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schifer CA, Schwartzberg L, Somerfeld MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolf AC. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205. (Pubitemid 46638957)
42. Cheang M, Chia SK, Tu D, Jiang S, Shepherd LE, Pritchard KI, Nielsen TO. Anthracyclines in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEF [abstract 519]. J Clin Oncol 2009;27(Suppl.):11s.